Stem Cell Clinic

Biotechnology Reagents Market Analysis and Forecast by Rapid Growth Rate 2020 Value Share Analysis by Regions, Industry Size, Key Insights till 2024 -…

By Stell Cell Research

Waters Corp.

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14245410

Key Market Trends:

Chromatography is Expected to Hold Significant Market Share in the Type of Analytical Reagents

Chromatography is a separation technique mainly used in drug discovery to validate the specificity, sensitivity, and purity of drugs. Chromatographic procedures have been largely used for analytical procedures and methods validation for drugs and biologics. Chromatographic techniques provide accurate results to validate characters, such as specificity, linearity, accuracy, precision, range, quantitation limit, and detection limit of various drugs. Chromatography reagents are used in a variety of applications, including high-performance liquid chromatography (HPLC), ion chromatography, flash chromatography, and complexometric titration. These reagents provide more precise, cost-effective separations, superior reproducibility, and accurate results in all forms of analytical chromatography. Since the chromatography techniques are well-established across the world, the demand for their reagents are consistently high for various pathological and academic purposes.

North America Dominates the Market and is Expected to Dominate in the Forecast Period

North America dominates the biotechnology reagents market and incurs the highest expenditure for global R&D. The United States accounted for the largest share in 2018. The North American segment is on a rise, due to various ongoing research in biological sciences, considerable investments by various biotechnology companies, and the consistently increasing utilization of biotechnology reagents in the market. Owing to the ongoing research and outsourcing activities in the field of life science, Asia-Pacific also has lucrative opportunities for growth over the forecast period.

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14245410

Detailed TOC of Biotechnology Reagents Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 High Research and Development Expenditure by Biotechnology Companies 4.2.2 Increasing Interest in Stem Cell Research 4.2.3 Rise in Number of Biotechnology Firms 4.3 Market Restraints 4.3.1 Stringent Government Regulations for Approval of Reagents 4.3.2 High Price of Biopharmaceuticals 4.4 Porters Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 Technology 5.1.1 Life Science Reagents 5.1.1.1 PCR 5.1.1.2 Cell Culture 5.1.1.3 Hematology 5.1.1.4 In-vitro Diagnostics 5.1.1.5 Others 5.1.2 Analytical Reagents 5.1.2.1 Chromatography 5.1.2.2 Mass Spectrometry 5.1.2.3 Electrophoresis 5.1.2.4 Flow Cytometry 5.1.2.5 Other Analytical Reagentss 5.2 Application 5.2.1 Protein Synthesis and Purification 5.2.2 Gene Expression 5.2.3 DNA and RNA Analysis 5.2.4 Drug Testing 5.2.5 Other Applications 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 Germany 5.3.2.2 United Kingdom 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Abbott Laboratories 6.1.2 Agilent Technologies 6.1.3 Beckman Coulter 6.1.4 Becton Dickinson & Company 6.1.5 Bio-Rad Laboratories 6.1.6 GE Healthcare 6.1.7 Siemens Healthcare 6.1.8 Sigma Aldrich Corporation 6.1.9 Thermo Fisher Scientific Inc. 6.1.10 Waters Corp.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Pickle Metal Detector Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

Disposable Anesthesia Needles Market Size, Share | Growth Analysis by Revenue, Future Demand Status, Price Analysis by Types and Applications till 2020-2026

Ultrasound Needles Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

Loratadine Market Size | Share Forecast 2020 to 2026: Competition Analysis, Industry Growth by New Innovations, Top Players Analysis with COVID-19 Impact

Hard Adventure Sports Equipment Market Size and Share by Growth, Industry Drivers and Restraints, Global Opportunity, COVID-19 Impact on Topmost Players | Forecast 2020-2026

Baby Care Stations Market Share, Top Manufacturers 2020 Future Growth Rate, Industry Size, Business Strategy, Demand Status by 2026 Research Includes COVID-19 Analysis

Continue reading here:
Biotechnology Reagents Market Analysis and Forecast by Rapid Growth Rate 2020 Value Share Analysis by Regions, Industry Size, Key Insights till 2024 -...

Personalized Cell Therapies Market to Witness Astonishing Growth by 2025 – Owned

By Stell Cell Research

The selective research report on the GlobalPersonalized Cell Therapies Market2020 analyzes the market in detail alongside concentrating on huge market elements for the key players working in the market. Worldwide Personalized Cell Therapies Market Industry research report offers granulated at this point top to bottom examination of income share, advertise portions, income gauges and different areas over the globe.

Request free sample copy of this report at:https://www.precisionbusinessinsights.com/request-sample?product_id=17290&utm_source=daily&utm_medium=24

This report contains a total item outline and its extension in the market to characterize the key terms and give the customers a comprehensive thought of the market and its propensity. It completely assesses the worldwide Personalized Cell Therapies Market advertise with alternate points of view to give a nitty gritty, instructive, and precise investigation of local development, rivalry, showcase division, and other significant viewpoints.

The following players are covered in this report are:

PCT Cell Therapy Services, LLC (U.S) S. Stem Cell, Inc. (U.S) Bellicum Pharmaceuticals, Inc. (U.S) Saneron CCEL Therapeutics, Inc. (U.S) StemGenex (U.S) Vericel Corporation.(U.S) Cytori Therapeutics Inc.(U.S.) MolMed S.p.A. (Italy)

Personalized Cell Therapies Market segmentation by Types:

Hematopoietic Stem Cell Skeletal Muscle Stem Cell Mesenchymal Stem Cells Lymphocytes Others

Applications can be segmented as follows:

Cardiovascular Disorders Diabetes Neurological Disorders Cancer Others

The statistical surveying insight report on title Global Personalized Cell Therapies Market gives stick guide examination toward changing focused elements and a forward-looking viewpoint on changed variables driving or limiting industry development. The Personalized Cell Therapies Market industry report gives vital and helper information which is spoken to in pie-graphs, tables, methodical outline, and item charts.

Request Customization at:https://www.precisionbusinessinsights.com/request-customisation?product_id=17290&utm_source=daily&utm_medium=24

The Personalized Cell Therapies Market Report likewise decide the economic situations including the item value, particular, inquire about approach, money related and specialized subtleties which will extend the market activities. The Market research report gives the most recent industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and gainfulness.

Key Features of the Report: The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)

The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies

The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

The report tracks recent innovations, key developments and startups details that are actively working in the market

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market

About Us: Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us: [emailprotected] PH +1-866-598-1553

Read the original here:
Personalized Cell Therapies Market to Witness Astonishing Growth by 2025 - Owned

Former SEC Head Coach, AD Hospitalized With COVID-19 – The Spun

By Stem Cell Doctors

Late Friday night, Alabama athletic director Greg Byrne shared a statement from former Alabama AD Bill Battle.

In the statement, Battle revealed he has been hospitalized with COVID-19. The former Tennessee Volunteers head coach said doctors expect him to make a full recovery.

I appreciate the prayers and well-wishes from so many, and want to let you know that Im stable and resting comfortably, he said. Ive got great doctors and nurses at UAB looking after me and expect to make a full recovery. Time and patience are important in the meantime.

Byrne took over for Battle as the Crimson Tides athletic director after Battle retired. Battle served as Alabamas athletic director from 2013-17.

Continued thoughts and prayers for Coach Battle for a full recovery. pic.twitter.com/bfXyNoDQRI

Greg Byrne (@Greg_Byrne) August 1, 2020

The 78-year-old began battling a form of cancer in 2014 and had stem cell transplants in 2016. Despite battling through the cancer treatments, he remained on the job as Alabamas athletic director.

Battle played his college football at Alabama, where he played under head coach Bear Bryant. He eventually got into coaching and served as an assistant at Army and Tennessee.

Battle took over as the head coach of the Volunteers in 1970 and led the team to an 11-1 record. In seven seasons as the head coach at Tennessee, he racked up a 59-22-2 record. He led the team to five bowl games, going 4-1 in those games.

We hope the former coach and AD has a speedy recovery.

Andrew McCarty is a writer for The Spun.

Here is the original post:
Former SEC Head Coach, AD Hospitalized With COVID-19 - The Spun

Think You Might Have NMOSD? Diagnosis May Take a While – HealthCentral.com

By Stem Cell Doctors

If youre suddenly experiencing blurred vision, numb limbs, relentless vomiting, or hiccups that last for days on end, you probablyno, you definitelywant to know whats going on, stat. But getting an accurate diagnosis for these unsettling symptoms isn't always straight forward. While theyre the classic signs of the autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), they can ring true for other conditions, too. So, it may take some sleuthing work before your doctor can put all the pieces together and get you on the right treatment path. Heres why:

NMOSD, a.k.a. Devics disease, accounts for just 2% of all demyelinating diseasesthose that damage the myelin sheath, the protective covering on your nervesso theres a good chance your primary care physician has never had a single patient with the disease. NMOSD attacks myelin on the optic nerve (which carries visual info from the eyes to the brain), the spinal cord, and sometimes the brainstem, leading to a wide range of symptoms that affect vision, balance, and even bladder and bowel function.

Symptoms develop over a period of a few days and peak within a week to 10 days, says Elias Sotirchos, M.D., director of the Neuromyelitis Optica Clinic at Johns Hopkins University in Baltimore. But if you were to google your symptoms (and we suspect you already have), youll see that theres a lot of overlap with other conditions including multiple sclerosis (MS), lupus, and even a brain tumor. So, before your doc lands on an NMOSD diagnosis, he may considerand potentially try to rule outthese other, more common issues first.

If you have blurry vision and throbbing eye painwhich can happen because NMOSD often causes a condition called optic neuritis (ON), leading to inflammation of the optic nerveyoud expect your doc to find some evidence of it when looking into your eyes during a regular eye exam. But with NMOSD, thats not always the case.

Optic disc swelling may not be present, says Dr. Sotirchos. Getting an ON diagnosis, then, comes from other parts of of an eye exam, a thorough patient history, and an optical coherence tomography (OCT) scan. This non-invasive diagnostic test can help spot swelling and damage of nerves in the back of the eye, and can also help nail an ON diagnosis, he adds. An MRI can also be done to ID which part of the nerve is involved.

ON happens in about half of all MS cases. About 20% of the time, its one of the first symptoms of that condition, according to research published in the journal Eye and Brain. So, if you go to your doctor with sudden vision loss or pain behind one or both eyes, your doctor may initially suspect MS.

And to confuse matters more, NMOSD was once considered a variant of MS, not a completely separate disease. Up until about 15 years ago, if a patient came in with [these symptoms], they would be diagnosed with MS, says Patricia Coyle, M.D., interim chair of the department of neurology at Stony Brook University in Stony Brook, NY.

Waking up to one or both limbs feeling weak, numb, or even paralyzed can be pretty scary. Or maybe you cant control your bladder, or urinate at all. These are things that can happen with you have transverse myelitis (TM). TM is diagnosed through a medical history and a neurological exam, as well as an MRI to look for spinal cord lesions that are typical with TM.

But your physician isnt finished there. He has to figure out why you have it. TM can signal NMOSD or MS, but it can also stem from other autoimmune disorders, vascular causes, and infections, as well as compression from a mass or even unexplained injury. So these other possibilities may need to be consideredand then rejectedbefore NMOSD emerges as the likely cause of your TM symptoms.

If your brainstem is the target of an NMOSD attacka rare occurrence in an already rare diseaseyour symptoms, while intense, may not immediately point to this condition.

NMOSD brainstem attacks arent as common as ON and TM. They happen in just 10% of cases. Nausea and vomiting might be dismissed as the flu or even food poisoning. Its only after youve been throwing up for daysor even weeksthat your doctor may start looking for other causes.

Hiccups are usually benign and can be triggered from carbonated beverages, alcohol, stress, eating too much, or swallowing air. But when they linger for more than 48 hours, your doctor may suspect nerve damage or irritation caused by reflux or even a cyst or tumor, central nervous system conditions including MS and stroke, as well as metabolic diseases (such as diabetes and kidney disease) before determining theyre actually the result of an NMOSD attack.

Fortunately, there are some highly specific blood tests that can tell docs if you have NMOSD. Back in 2004, researchers discovered that about 75% of people with NMOSD have antibodies in their blood called aquaporin-4 antibodies (AQP4-IgG). These antibodies target water channels (aquaporins) located on astrocytes, a type of cell in the central nervous system. We now realize that NMOSD is [usually] an immune attack on aquaporin-4, says Dr. Coyle.

About 20% of people with NMOSD dont have AQP4-IgG, but they may have another kind of antibody: myelin oligodendrocyte glycoprotein (MOG-IgG), a protein in the outer layer of the myelin sheath. Identifying these two antibodies have helped docs get to an NMOSD diagnosis faster than before (and rule out MS in one fell swoop).

Even so, getting your results can take weeks, leaving you, well, a bundle of nerves. And a small percentage of people with NMOSD wont have either antibody, even though they have all the classic NMOSD symptoms. If this happens to you, after your bloodwork comes back your doctor may schedule more tests, including a spinal tap and an MRI.

There is some association between NMOSD and the autoimmune disorder lupus. Some people with NMOSD will test positive for antibodies associated with lupus, even if they dont have any signs of that condition, says Dr. Sotrichos. The overlap between NMO and lupus likely has to do with a shared genetic tendency to developing these two autoimmune diseases, he says.

Interestingly, those who do have lupus and symptoms of ON and TM often carry AQP4-1gG antibodiesas many as 60%, suggests a study in Lupus. People with lupus with transverse myelitis, optic neuritis, or other neurological symptoms consistent with NMOSD should be tested for AQP4-IgG at that time, Dr. Sotirchos advises. In most cases, those who are positive for AQP4-IgG have actual signs of NMOSD, suggesting it may be co-existing with lupus.

As if this rare disease isnt complex enough, there are two types: relapsing, which is when you get repeated attacks with months or even years of remission in between, and monophasic, a single attack that lasts for at least a month or two. Your doctor wont know which one you have right away, but your bloodwork holds some clues: AQP4-IgG-positive NMOSD is typically treated as relapsing.

Those with MOG-IgG antibodies may have a monophasic attack, but its a wait-and-see game. If patients [with MOG-IgA antibodies] are followed long enough, the vast majority will have a relapse, says Dr. Sotirchos. So, doctors treat most cases as if they are the relapsing type.

Now that you have an official diagnosis of NMOSD, you might sigh with relief to finally have a name for what youve been experiencingeven as you battle worry, or even fear. Deep breath. Know that in the past few years powerful new treatment options have emerged to reduce the likelihood of another attack occurringto help keep you symptom-free in the future.

More here:
Think You Might Have NMOSD? Diagnosis May Take a While - HealthCentral.com

American Academy of Stem Cell Physicians is Hosting an FDA Safety Panel, Session is Now Free to the Public – Yahoo Finance

By Stem Cell Treatment

Important FDA Safety Panel discussion open and free to the public Aug. 1-3, 2020

MIAMI, July 29, 2020 /PRNewswire/ --An FDA Safety Panel discussion will be held virtually by the American Academy of Stem Cell Physicians (AASCP) Aug.1-3, 2020, with guest speakerFDA Director Dr. Peter Marks. This is a highly anticipated session which will discuss the growing safety concerns of the industry.

The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought-after Safety StandardsPanel session will be hosted VIRTUALLY by AASCP on Aug. 1-3. 2020; guest of honor isDr. Peter Marks, FDA Director of CBER. The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open and free to the public, covering the growing safety concerns of the industry.

The Safetypanel discussion will discuss advancements in development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. The Safety Panel discussion willbringtogether experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory and patient decision-making.

According to AASCP, if physicians are using biologics in their practice, whether they are using SVF, PRP, bone marrow, UCB, amniotic products, exosomes, xenograftsor peptides, there are key considerations to take into account to achieve the best safety for their patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory they work with. AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for their patients. Sales agents typically do not have a medical or scientific background.

The President for the AASCP, Dr. Martin Dayton,said earlier: "The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy fromSVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever-growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Aug. 1-3, 2020, is to help get rid of the bad actors that are damaging the field for everyone."

The importance of this virtual conference coincides with the ever-emerging growthof the globalregenerative medicine marketwhich is expected to reachUSD 79.8 billionby 2024, at aCAGR of 20.5%from 2018 to 2024. Factors driving the growth of the market areincreasing prevalence of degenerative and chronic diseases, technological advancements in nanotechnology, bioengineering and stem cell therapy, and increasing geriatric population across the globe.TheAASCP virtual meeting is set for Aug. 1, 2020.List of speakers is available at http://www.aascp.net.

Due to COVID-19, the meeting will take place virtually.Thisis an effective way to ensure that everyone that wishes to participate, but cannot travel, can. Students, educators and physicians will not have to miss out on all the important topics that AASCP has on the pipeline.

Virtual Workshop Lecturers will virtually demonstrate their techniques live via their professional locations. These virtualinteractive workshops will feature small participant-to-instructor ratios with a customized curriculum focusing on developing hands-on skills. Each technique will be taught by experts in the field, using didactic sessions with dynamic multimedia presentations, live demonstrations and scanning on live models, as well as phantoms.

AASCP spokesmanDr. A.J.Farshchianexplains, "We will duplicate everything we did in our past meetings such as offer CME credits, have lectures, workshops, discuss FDA safety standards, have board examinations and a virtual graduation ceremony. AASCP is offering this virtual meeting so that nobody misses out on the education."

To join the free session via Zoom, please click on the link below at 11a.m. this Saturday.

Join Zoom Meeting: https://aascp.zoom.us/j/4150937630

Meeting ID: 415 093 7630

The American Academy of Stem Cell Physicians (AASCP) is a non-profit organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. Secondarily, the AASCPaims to serve as an educational resource for physicians, scientists, and the public in diseases that can be caused by physiological dysfunction that isameliorable to medical treatment.

For further information, please contact MarieBarbaat AASCP at 305-891-4686or visit us at http://www.aascp.net.

Related Images

virtual-conference-aug-1-3-2020.jpeg Virtual Conference Aug. 1-3, 2020

aascp.png AASCP

Related Links

Guest Speaker Dr. Peter Marks, FDA Director

AASCP zoom meeting

View original content to download multimedia:http://www.prnewswire.com/news-releases/american-academy-of-stem-cell-physicians-is-hosting-an-fda-safety-panel-session-is-now-free-to-the-public-301102157.html

SOURCE American Academy of Stem Cell Physicians

See the original post:
American Academy of Stem Cell Physicians is Hosting an FDA Safety Panel, Session is Now Free to the Public - Yahoo Finance

Amniotic Fluid Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2018 – 2026 – Market Research Correspondent

By Stem Cell Treatment

With having published myriads of reports, PMR imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, PMR serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Amniotic Fluid Stem Cell Therapy market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Amniotic Fluid Stem Cell Therapy market.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/23101

The Amniotic Fluid Stem Cell Therapy market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/23101

What does the Amniotic Fluid Stem Cell Therapy market report contain?

Readers can get the answers of the following questions while going through the Amniotic Fluid Stem Cell Therapy market report:

And many more

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/23101

Here is the original post:
Amniotic Fluid Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2018 - 2026 - Market Research Correspondent

Rockies vs. Athletics – Game Recap – July 28, 2020 – ESPN

By Platelet Rich Plasma Injections

OAKLAND, Calif. -- Sam Hilliard homered for the first time this season, Antonio Senzatela pitched out of an early jam on his way to a rare road win, and the Colorado Rockies beat the Oakland Athletics 8-3 Tuesday night.

Charlie Blackmon had two hits, David Dahl drove in a pair of runs and Nolan Arenado made up for an uncharacteristic fielding error with a single and sacrifice fly to help the Rockies to their third straight win following an opening day loss to Texas.

"We've got a good pitching staff always and this year we've been doing good," Senzatela said. "We were just working for that in the offseason, even through the quarantine. I think we deserve this."

Hilliard was hitless going into the day before doubling off A's starter Daniel Mengden in the second and then homering in the fourth. Hilliard, who homered in his major league debut last August, laced a 2-2 pitch into the right-field stands after Raimel Tapia singled.

"Sam's blast, the breaking ball in the seats was a great swing," Rockies manager Bud Black said. "I like the double the other way. We saw Sam do that a number of times last year, take pitches away from him, hit them to left field. The home run gave us a big lift."

Senzatela worked himself into an early jam but got Oakland slugger Khris Davis to pop out with the bases loaded in the first on the way to his first win on the road since July 5, 2019. The right-hander had dropped five straight away from home since then.

Senzatela (1-0) allowed two runs (one earned) and six hits in five innings. He walked three and struck out three.

"I threw too many pitches in the first inning but I just put on myself, `I need to make it through five to give the team a chance to win,' and I did it," Senzatela said.

Tyler Kinley, Daniel Bard and Carlos Estevez combined to two-hit the A's over the final four innings.

Ramon Laureano had two hits and Mark Canha added a sacrifice fly for the A's, who were attempting to go 4-1 for the first time since 2010.

Oakland manager Bob Melvin had been hopeful of resting his taxed bullpen but didn't get the chance after Mengden (0-1) lasted four innings and gave up three runs on five hits.

"Strike one can be a problem for him sometimes," Melvin said. "He tries to be a little too fine at times. It's getting the pitch count down and trying to get the other team to put the ball in play earlier in the count."

The Rockies tacked on a pair in the fifth with four consecutive one-out hits and a sacrifice fly off A's reliever Jordan Weems in his major league debut. They scored three more in the eighth.

MILESTONE, BUT NO HITS

Davis moved into second place in games played by A's designated hitters but continued to struggle at the plate. He struck out twice, popped up and hit into a double play in four at-bats, dropping the Oakland slugger to 0 for 15 this season.

"I've said all along that leashes can be a little bit shorter when you struggle in 60 games," Melvin said. "It's like being in August right now. Some of the guys who have track records deserve a little bit of a longer leash. He's been really good for us over the years."

The game marked the 356th for Davis as the A's DH, moving him past Mitchell Page on the franchise list. Davis will have to wait until next season to break Dave Kingman's mark of 428.

TRAINER'S ROOM

Athletics: Mengden pitched in a game for the first time since undergoing elbow surgery in February. He was moved into the rotation as left-hander A.J. Puk deals with a strained throwing shoulder that landed him on the injured list to start the season and required cortisone and platelet-rich plasma injections. . T.J. McFarland, Jake Diekman and Yusmeiro Petit, all of whom pitched three times in Oakland's first four games, were rested.

UP NEXT

The two-game series ends Wednesday afternoon when Oakland's Frankie Montas (0-0, 2.25 ERA) makes his second start of the season against Colorado's German Marquez (0-1, 1.59) in a matchup of right-handers. Marquez's loss on opening day was his first in 16 interleague starts.

---

More AP MLB: https://apnews.com/MLB and https://twitter.com/AP-Sports

Read more:
Rockies vs. Athletics - Game Recap - July 28, 2020 - ESPN

Global Market Trends in the Cell and Gene Therapy Tools and Reagents Market 2020-2024 – GlobeNewswire

By Stem Cell Treatment

July 31, 2020 07:48 ET | Source: Research and Markets

Dublin, July 31, 2020 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools, and Reagents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Gene and cell therapy are emerging as important tools to treat human health. Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers. The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene-based diseases. As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

The scope of this study encompasses an investigation of the market's cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. This research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. The report analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Region

Chapter 5 Market Breakdown by End User

Chapter 6 Government Regulations

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/86txdi

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Formats available:

Go here to read the rest:
Global Market Trends in the Cell and Gene Therapy Tools and Reagents Market 2020-2024 - GlobeNewswire

Stem Cell Market Analysis and Forecast by Rapid Growth Rate 2020 Value Share Analysis by Regions, Industry Size, Key Insights till 2024 – Bulletin…

By Embryonic Stem Cells

International Stem Cell Corporation

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999718

Key Market Trends:

Oncology Disorders Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Cancer has a major impact on society in the United States and across the world. As per the estimation of National Cancer Institute, in 2018, 1,735,350 new cases of cancer were anticipated to get diagnosed in the United States, and 609,640 deaths were expected from the disease. This increasing medical burden is due to population growth. Bone marrow transplant or stem cell transplant is a treatment for some types of cancers, like leukemia, multiple myeloma, multiple myeloma, neuroblastoma, or some types of lymphoma.

Embryonic stem cells (ESC) are the major source of stem cells for therapeutic purposes, due to their higher totipotency and indefinite lifespan, as compared to adult stem cells with lower totipotency and restricted lifespan. However, the use of ESCs for research and therapeutic purposes is restricted and prohibited in many countries throughout the world, due to some ethical constraints. Scientists from the University of California, Irvine, created the stem cell-based approach to kill cancerous tissue while preventing some toxic side effects of chemotherapy by treating the disease in a more localized way.

Although the market shows positive growth, due to the growing focus of stem cell-based research that can further strengthen the clinical application, its expensive nature for stem cell therapy may still hamper its growth.

North America Captured The Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall stem cell market with the United States contributing to the largest share in the market. In 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System, announced the launch of a clinical trial, in order to assess the safety of neural stem cell-based therapy in patients with chronic spinal cord injury. Researchers hoped that the transplanted stem cells may develop into new neurons that could replace severed or lost nerve connections, and restore at least some motor and sensory functions. Such numerous stem cell studies across the United States have helped in the growth of the stem cell market.

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999718

Detailed TOC of Stem Cell Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increased Awareness about Umbilical Stem Cell 4.2.2 Increase in the Approval for Clinical Trials in Stem Cell Research 4.2.3 Growing Demand for Regenerative Treatment Option 4.2.4 Rising R&D Initiatives to Develop Therapeutic Options for Chronic Diseases 4.3 Market Restraints 4.3.1 Expensive Procedures 4.3.2 Regulatory Complications 4.3.3 Ethical and Moral Framework 4.4 Industry Attractiveness- Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Product Type 5.1.1 Adult Stem Cell 5.1.2 Human Embryonic Cell 5.1.3 Pluripotent Stem Cell 5.1.4 Other Product Types 5.2 By Therapeutic Application 5.2.1 Neurological Disorders 5.2.2 Orthopedic Treatments 5.2.3 Oncology Disorders 5.2.4 Diabetes 5.2.5 Injuries and Wounds 5.2.6 Cardiovascular Disorders 5.2.7 Other Therapeutic Applications 5.3 By Treatment Type 5.3.1 Allogeneic Stem Cell Therapy 5.3.2 Auto logic Stem Cell Therapy 5.3.3 Syngeneic Stem Cell Therapy 5.4 By Banking Service and Technology 5.4.1 Stem Cell Acquisition and Testing 5.4.2 Cell Production 5.4.3 Expansion 5.4.4 Sub-culture 5.4.5 Cryopreservation 5.5 By Type of Banking 5.5.1 Public 5.5.2 Private 5.6 Geography 5.6.1 North America 5.6.1.1 US 5.6.1.2 Canada 5.6.1.3 Mexico 5.6.2 Europe 5.6.2.1 UK 5.6.2.2 Germany 5.6.2.3 France 5.6.2.4 Italy 5.6.2.5 Spain 5.6.2.6 Rest of Europe 5.6.3 Asia-Pacific 5.6.3.1 China 5.6.3.2 Japan 5.6.3.3 India 5.6.3.4 Australia 5.6.3.5 South Korea 5.6.3.6 Rest of Asia-Pacific 5.6.4 Middle East & Africa 5.6.4.1 GCC 5.6.4.2 South Africa 5.6.4.3 Rest of Middle East & Africa 5.6.5 South America 5.6.5.1 Brazil 5.6.5.2 Argentina 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Osiris Therapeutics Inc. 6.1.2 Pluristem Therapeutics Inc. 6.1.3 Thermo Fisher Scientific 6.1.4 Qiagen NV 6.1.5 Sigma Aldrich Corporation 6.1.6 Becton, Dickinson and Company 6.1.7 Stem Cell Technologies Inc. 6.1.8 AllCells LLC 6.1.9 Miltenyi Biotec 6.1.10 International Stem Cell Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Lower Extremity Bone Fixation Screws Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

Managed Mobility Services Market Size Analysis with Industry Share 2020: Industry Trend, Business Growth, Segmentation, Competitors, and Forecast Details for 2024 | Industry Research.co

Cotton Balls Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

Thin Film SMD Resistors Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Ammonium Carbonate Market Key Developments by Global Size, Emerging Trends, Industry Analysis, Growth Status of Manufacturers, and Product Specification Forecast to 2020-2024

Medicinal Shampoo Market Share Value 2020 Industry Top Players, Trends, Global Growth Rate by Size Expansion Strategies by 2026 Report Includes COVID-19 Analysis

Read more:
Stem Cell Market Analysis and Forecast by Rapid Growth Rate 2020 Value Share Analysis by Regions, Industry Size, Key Insights till 2024 - Bulletin...

FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL – Pharmacy Times

By Stem Cell Treatment

FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL

A humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, tafasitamab-cxix received accelerated approval based on overall response rate (ORR). Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Globally, DLBCL is the most common type of non-Hodgkin lymphoma in adults. The aggressive disease is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs, and about 1 in 3 patients do not respond to initial therapy or relapsing thereafter.In the United States, approximately 10,000 patients are diagnosed with relapsed or refractory DLBCL who are not eligible for ASCT, each year.

The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of tafasitamab-cxix in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL. Results from the study showed an ORR of 55% (primary endpoint), including a complete response (CR) rate of 37%, and a partial response rate (PR) of 18%. The median duration of response (mDOR) was 21.7 months (key secondary endpoint).

Warnings and precautions for tafasitamab-cxix included infusion-related reactions (6%), serious or severe myelosuppression including neutropenia (50%), thrombocytopenia (18%), and anemia (7%); infections (73%), and embryo-fetal toxicity. Neutropenia led to treatment discontinuation in 3.7% of patients. The most common adverse reactions ( 20%) were neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite.

The FDA previously granted Fast Track and Breakthrough Therapy Designation for the tafasitamab-cxix and lenalidomide combination in treatment of relapsed or refractory DLBCL. FDA.

Tafasitamab-cxix is expected to be commercially available in the United States shortly, according to MorphoSys and Incyte, which plan to co-commercialize this therapy in the US. Incyte has exclusive commercialization rights outside the US.

REFERENCE

FDA Approves Monjuvi(tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [news release]. Planegg & Munich, Germany, and Wilmington, DE; July 31, 2020: MorphoSys and Incyte.https://www.businesswire.com/news/home/20200731005497/en.

View original post here:
FDA Approves Tafasitamab-cxix in Combination With Lenalidomide for the Treatment of DLBCL - Pharmacy Times

→←